185 related articles for article (PubMed ID: 9021658)
1. [Oral single-dose toxicity study of a new antineoplastic agent S-1, and its components, CDHP, and Oxo].
Hayashi T; Tanaka G; Irimura K; Hirota T; Ohmae S
J Toxicol Sci; 1996 Nov; 21 Suppl 3():495-504. PubMed ID: 9021658
[TBL] [Abstract][Full Text] [Related]
2. [A 13-week oral repeated dose toxicity study of a new antineoplastic agent S-1 in rats].
Hayashi T; Hasegawa H; Tanaka G; Ohmae S
J Toxicol Sci; 1996 Nov; 21 Suppl 3():505-26. PubMed ID: 9021659
[TBL] [Abstract][Full Text] [Related]
3. [An oral repeated dose toxicity study of a new antineoplastic agent S-1 in dogs. I. A 13-week repeated dose toxicity study. II. An ophthalmologic toxicity recovery study].
Hayashi T; Yamaguchi S; Kito S; Tanaka G; Kurokawa K; Hirota T
J Toxicol Sci; 1996 Nov; 21 Suppl 3():527-44. PubMed ID: 9021660
[TBL] [Abstract][Full Text] [Related]
4. [Reproductive and developmental toxicity study of a new antineoplastic agent, S-1 (I)--Fertility study in rats by oral administration].
Shinomiya M; Imamura K; Izumi K
J Toxicol Sci; 1996 Nov; 21 Suppl 3():589-602. PubMed ID: 9021663
[TBL] [Abstract][Full Text] [Related]
5. [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
Shirasaka T; Shimamoto Y; Kato T; Fukushima M
Gan To Kagaku Ryoho; 1998 Feb; 25(3):371-84. PubMed ID: 9492831
[TBL] [Abstract][Full Text] [Related]
6. [Mutagenicity study of a new antineoplastic agent S-1, and its components, CDHP, and Oxo].
Ohuchida A; Kouchi Y; Sato S; Maeda Y
J Toxicol Sci; 1996 Nov; 21 Suppl 3():675-89. PubMed ID: 9021668
[TBL] [Abstract][Full Text] [Related]
7. [Immunotoxic effects of a new antineoplastic agent S-1 in mice--comparison with S-1, UFT and 5-FU].
Kouchi Y; Maeda Y; Morinaga H; Ohuchida A
J Toxicol Sci; 1996 Nov; 21 Suppl 3():691-701. PubMed ID: 9021669
[TBL] [Abstract][Full Text] [Related]
8. Possible regulation of 5-fluorouracil-induced neuro- and oral toxicities by two biochemical modulators consisting of S-1, a new oral formulation of 5-fluorouracil.
Kato T; Shimamoto Y; Uchida J; Ohshimo H; Abe M; Shirasaka T; Fukushima M
Anticancer Res; 2001; 21(3B):1705-12. PubMed ID: 11497250
[TBL] [Abstract][Full Text] [Related]
9. Reduction of 5-fluorouracil (5-FU) gastrointestinal (GI) toxicity resulting from the protection of thymidylate synthase (TS) in GI tissue by repeated simultaneous administration of potassium oxonate (Oxo) in rats.
Yoshisue K; Hironaga K; Yamaguchi S; Yamamoto A; Nagayama S; Kawaguchi Y
Cancer Chemother Pharmacol; 2000; 46(1):51-6. PubMed ID: 10912578
[TBL] [Abstract][Full Text] [Related]
10. [Reproductive and developmental toxicity study of a new antineoplastic agent, S-1 (III)--Teratological study in rabbits by oral administration].
Shinomiya M; Yukiyama S; Ikebuchi K
J Toxicol Sci; 1996 Nov; 21 Suppl 3():619-41. PubMed ID: 9021665
[TBL] [Abstract][Full Text] [Related]
11. [Reproductive and developmental toxicity study of a new antineoplastic agent, S-1 (II)--Teratological study in rats by oral administration].
Yukiyama S; Shinomiya M; Ikebuchi K; Sato T
J Toxicol Sci; 1996 Nov; 21 Suppl 3():603-18. PubMed ID: 9021664
[TBL] [Abstract][Full Text] [Related]
12. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators.
Shirasaka T; Shimamato Y; Ohshimo H; Yamaguchi M; Kato T; Yonekura K; Fukushima M
Anticancer Drugs; 1996 Jul; 7(5):548-57. PubMed ID: 8862723
[TBL] [Abstract][Full Text] [Related]
13. [Reproductive and developmental toxicity study of a new antineoplastic agent, S-1 (IV)--Perinatal and postnatal study in rats by oral administration].
Furuhashi T; Kato M; Fujimura T; Koida M
J Toxicol Sci; 1996 Nov; 21 Suppl 3():643-59. PubMed ID: 9021666
[TBL] [Abstract][Full Text] [Related]
14. [A 26-week oral repeated dose toxicity study of a new antineoplastic agent S-1 in rats].
Hakoi K; Hayashi T; Ohmae S; Besshi K
J Toxicol Sci; 1996 Nov; 21 Suppl 3():545-60. PubMed ID: 9021661
[TBL] [Abstract][Full Text] [Related]
15. [A 52-week oral toxicity study of a new antineoplastic agent S-1 in dogs].
Kitajima S; Okamura T; Kobayashi K; Watari N; Inoue H; Enomoto M; Yamaguchi S
J Toxicol Sci; 1996 Nov; 21 Suppl 3():561-88. PubMed ID: 9021662
[TBL] [Abstract][Full Text] [Related]
16. Potassium oxonate, an enzyme inhibitor compounded in S-1, reduces the suppression of antitumor immunity induced by 5-fluorouracil.
Yamashita T; Ueda Y; Fuji N; Itoh T; Kurioka H; Shirasaka T; Yamagishi H
Cancer Chemother Pharmacol; 2006 Aug; 58(2):183-8. PubMed ID: 16317557
[TBL] [Abstract][Full Text] [Related]
17. [Antigenicity tests of a new antineoplastic agent S-1].
Maeda Y; Morinaga H; Izumi K; Ikebuchi K; Kouchi Y
J Toxicol Sci; 1996 Nov; 21 Suppl 3():661-73. PubMed ID: 9021667
[TBL] [Abstract][Full Text] [Related]
18. The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors.
Peters GJ; Noordhuis P; Van Groeningen CJ; Giaccone G; Holwerda U; Voorn D; Schrijvers A; Schornagel JH; Beijnen JH; Fumoleau P; Schellens JH
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4072-6. PubMed ID: 15217941
[TBL] [Abstract][Full Text] [Related]
19. Increased intestinal permeability correlates with gastrointestinal toxicity among formulations of the fluorouracil analogue tegafur in rats.
Korenaga D; Honda M; Yasuda M; Inutsuka S; Nozoe T; Tashiro H
Eur Surg Res; 2002; 34(5):351-6. PubMed ID: 12364819
[TBL] [Abstract][Full Text] [Related]
20. Diamine oxidase, a plasma biomarker in rats to GI tract toxicity of oral fluorouracil anti-cancer drugs.
Moriyama K; Kouchi Y; Morinaga H; Irimura K; Hayashi T; Ohuchida A; Goto T; Yoshizawa Y
Toxicology; 2006 Jan; 217(2-3):233-9. PubMed ID: 16278042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]